The potential role of Bi-specific antibodies in acute myeloid leukemia

被引：4

作者：

Yilmaz, Musa ^{[1
]}

Ravandi, Farhad ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1400 Holcombe Blvd,Unit 428, Houston, TX 77030 USA

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2020年 / 33卷 / 04期

关键词：

Bispecific antibody; BiTE; DART; BiKE; TriKE; Tandem antibody; AML; Immunotherapy; T-CELL ENGAGER; RECEPTOR-ALPHA CHAIN; STEM-CELL; MACROPHAGE ACTIVATION; MONOCLONAL-ANTIBODY; AMG; 330; TARGET; EXPRESSION; CD123; CD33;

D O I：

10.1016/j.beha.2020.101218

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bispecific antibodies consist of antigen recognition sites from two or more antibodies redirecting effector immune cell against target on tumor cells. Rapidly evolving medical technologies enabled engineering and development of recombinant protein products, and this, combined with interest from the pharmaceutical industry, further advanced the bispecific antibody research. Over 50 different types of bispecific antibody constructs are now being manufactured and explored in ongoing or future clinical trials. In this review, we will summarize the available data for bispecific antibodies developed and being investigated for the treatment of patients with acute myeloid leukemia.

引用

页数：7

共 50 条

[31] NEW MODEL TO QUANTIFY THE IN VITRO PHARMACOLOGICAL ACTIVITY OF BI-SPECIFIC ANTIBODIES IN HAEMATOLOGIC MALIGNANCIES
Primo, D.
Martinez Cuadron, D.
Montesinos, P.
De la Serna, J.
Ribera, J. Ma
Vives, S.
Bergua, J.
Perez de Oteyza, J.
Serrano, J.
Gorrochategui, J.
Vicente Ma, L.
Gomez, C.
Martinez Lopez, J.
Hernandez, P.
Ballesteros, J.
HAEMATOLOGICA, 2017, 102 : 37 - 38
[32] Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
Karie Runcie
Daniel R. Budman
Veena John
Nagashree Seetharamu
Molecular Medicine, 2018, 24
[33] Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
Runcie, Karie
Budman, Daniel R.
John, Veena
Seetharamu, Nagashree
MOLECULAR MEDICINE, 2018, 24
[34] Bi-specific antibodies with high antigen-binding affinity identified by flow cytometry
Xu, Liming
Zhang, Yu
Wang, Qiuying
Zhao, Jingzhuang
Liu, Miao
Guo, Mo
Jiang, Yuanyuan
Cao, Hongwei
Li, Qingcui
Ren, Guiping
Li, Deshan
INTERNATIONAL IMMUNOPHARMACOLOGY, 2015, 24 (02) : 463 - 473
[35] AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia
Vandewalle, Niels
Satilmis, Hatice
Verheye, Emma
Fan, Rong
Wang, Yanmeng
De Groof, Timo W. M.
Bridoux, Jessica
Kerre, Tessa
De Beule, Nathan
De Becker, Ann
De Bruyne, Elke
Menu, Eline
Vanderkerken, Karin
Breckpot, Karine
Devoogdt, Nick
De Veirman, Kim
THERANOSTICS, 2024, 14 (07): : 2656 - 2674
[36] Role of interleukins in acute myeloid leukemia
Wang, Yin
Tang, Xiao
Zhu, Yu
Yang, Xiao-xiao
Liu, Bei
LEUKEMIA & LYMPHOMA, 2023, 64 (08) : 1400 - 1413
[37] Role of nucleophosmin in acute myeloid leukemia
Meani, Natalia
Alcalay, Myriam
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (09) : 1283 - 1294
[38] The role of clofarabine in acute myeloid leukemia
Ghanem, Hady
Kantarjian, Hagop
Ohanian, Maro
Jabbour, Elias
LEUKEMIA & LYMPHOMA, 2013, 54 (04) : 688 - 698
[39] A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential
Wang, Jiaqi
Bardelli, Marco
Espinosa, Diego A.
Pedotti, Mattia
Ng, Thiam-Seng
Bianchi, Siro
Simonelli, Luca
Lim, Elisa X. Y.
Foglierini, Mathilde
Zatta, Fabrizia
Jaconi, Stefano
Beltramello, Martina
Cameroni, Elisabetta
Fibriansah, Guntur
Shi, Jian
Barca, Taylor
Pagani, Isabel
Rubio, Alicia
Broccoli, Vania
Vicenzi, Elisa
Graham, Victoria
Pullan, Steven
Dowall, Stuart
Hewson, Roger
Jurt, Simon
Zerbe, Oliver
Stettler, Karin
Lanzavecchia, Antonio
Sallusto, Federica
Cavalli, Andrea
Harris, Eva
Lok, Shee-Mei
Varani, Luca
Corti, Davide
CELL, 2017, 171 (01) : 229 - +
[40] Erratum: Acute myeloid leukemia targets for bispecific antibodies
S S Hoseini
N K Cheung
Blood Cancer Journal, 2017, 7 : e552 - e552

← 1 2 3 4 5 →